Establishment Labs submits final PMA module for Motiva to FDA; Q4 revenue $43.8M, up 24% YoY; guides 2023 $200-210M

ESTABLISHMENT LABS HOLDINGS INC.

2022-FY EPS reported -$3.08 revenue$161,700,000

Submitted fourth and final module to U.S. FDA for premarket approval of Motiva Implants in the U.S.
Q4 2022 revenue $43.8M, up 24.1% YoY; operating loss $13.6M vs $14.2M loss in prior year.
2023 revenue guidance $200M-$210M, representing 24%-30% growth over 2022.
Cash balance $66.4M as of Dec 31, 2022; increased $12.9M from prior year.
Mia Femtech commercialization on track; China approval expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ESTABLISHMENT LABS HOLDINGS INC. reported the quarter ended December 31, 2022 results: revenue $43.8 million, net income $13.6 million. Guidance initiated.

Period: the quarter ended December 31, 2022
Revenue: $43.8 million
Net income: $13.6 million
Guidance: initiated
Result: reported results

Exact text from the filing

Total revenue for the quarter ended December 31, 2022 was $43.8 million compared to $35.3 million for the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ESTABLISHMENT LABS HOLDINGS INC. updated its the year ended December 31, 2022 guidance (initiated).

Period: the year ended December 31, 2022
Guidance: initiated
Result: reported results

Exact text from the filing

The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022 and provided 2023 guidance.

View on SEC.gov

Browse all earnings releases →

ESTABLISHMENT LABS HOLDINGS INC. filing history →

Source: SEC EDGAR

accession 0001688757-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.